Publication Name	World Journal of Nephrology
Manuscript ID	3858
Country

Received	2013-05-29 08:19
Peer-Review Started	2013-05-29 18:42
To Make the First Decision	2013-07-19 08:24
Return for Revision	2013-07-22 13:48
Revised	2013-08-02 14:48
Second Decision	2013-08-29 07:55
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-08-29 09:59
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-23 19:02
Publish the Manuscript Online	2013-11-04 12:41

ISSN	2220-6124 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Brief Articles
Article Title	Retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease
Manuscript Source
All Author List	Keng-Thye Woo, Hui-Lin Choong, Kok-Seng Wong, Han-Kim Tan, Marjorie Foo, Fook-Chong Stephanie, Evan JC Lee, Vathsala Anantharaman, Grace SL Lee and Choong-Meng Chan
Funding Agency and Grant Number
Corresponding Author	Keng-Thye Woo, Professor, Department of Renal Medicine Singapore General Hospital, Outram Road, 169608, Singapore. woo.keng.thye@sgh.com.sg
Key Words	Aliskiren; Chronic kidney disease disease; Clinical trial
Core Tip	The Aliskiren trial in type 2 diabetes using Cardio-Renal Endpoints (ALTITUDE) study was able to unmask serious adverse events like ischemic heart disease and strokes because it had included Cardio-Renal Endpoints among its primary end points. It may be advisable to require future trials on drugs which could impact on the kidneys, heart and brain to have similar Cardio-Renal Endpoints or Cardio-Neuro-Renal End points to further ensure therapeutic safety of the trial drug. Our modest study compared to the magnitude of the ALTITUDE study still managed to detect the problem of hyperkalaemia in the group treated with Combination therapy with Aliskiren and ARB. Based on our study it would appear that the findings of the ALTITUDE study would also apply to non-diabetic Chronic Kidney Disease patients.
Publish Date	2013-11-04 12:41
Citation	Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Stephanie FC, Lee EJC, Anantharaman V, Lee GSL, Chan CM. A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease. World J Nephrol 2013; 2(4): 129-135
URL	http://www.wjgnet.com/2220-6124/full/v2/i4/129.htm
DOI	http://dx.doi.org/10.5527/wjn.v2.i4.129

Full Article (PDF)	WJN-2-129.pdf
Manuscript File	3858-Review.docx
Answering Reviewers	3858-Answering reviewers.pdf
Copyright License Agreement	3858-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Aliskiren Study IRB.pdf
Non-Native Speakers of English Editing Certificate	3858-Language certificate.pdf
Peer-review Report	3858-Peer review.pdf
Scientific Editor Work List	3858-Scientific editor work list.doc